Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Press Releases - Voyager Therapeutics Inc.

    ir.voyagertherapeutics.com/press-releases

    LEXINGTON, Mass. , July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024 .

  3. Get the latest Voyager Therapeutics, Inc. (VYGR) stock news and headlines to help you in your trading and investing decisions.

  4. Latest News. View All News. 09.16.2024. Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development... 09.05.2024. Voyager Enters into License for Next-Generation Capsid, Bringing Partnered... 08.29.2024. Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule...

  5. Voyager Therapeutics Announces License Option Agreement with...

    ir.voyagertherapeutics.com/news-releases/news-release-details/voyager...

    Voyager will receive $54 million upfront and is entitled to receive up to $37.5 million in exercise fees for options for three initial CNS targets, exercisable by Novartis within 12 months of signing.

  6. Voyager Therapeutics Reports First Quarter 2024 Financial and...

    ir.voyagertherapeutics.com/news-releases/news-release-details/voyager...

    LEXINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported first quarter 2024 financial and operating results.

  7. Find the latest Voyager Therapeutics, Inc. (VYGR) stock quote, history, news and other vital information to help you with your stock trading and investing.

  8. Voyager Therapeutics Presents Data for Second-Generation, TRACER...

    finance.yahoo.com/news/voyager-therapeutics-presents-data-second-100000925.html

    A potent SOD1 RNAi transgene packaged in a novel TRACER™-evolved capsid and administered IV in NHPs led to a favorable safety profile and significant reductions of SOD1 mRNA in critical spinal ...

  9. Voyager Therapeutics Enters Capsid License Agreement and -...

    www.globenewswire.com/news-release/2024/01/02/2802564/36461/en/Voyager...

    LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic...

  10. Voyager Therapeutics shares soar 32% on news of deal with...

    www.marketwatch.com/story/voyager-therapeutics-shares-soar-32-on-news-of-deal...

    Voyager Therapeutics Inc.’s stock VYGR, -0.96% soared 32% early Tuesday, after the Lexington, Mass.-based biotech announced a new license agreement with Novartis Pharma AG, a unit of Novartis...

  11. Voyager Therapeutics Announces Proposed Public Offering - Yahoo...

    finance.yahoo.com/news/voyager-therapeutics-announces-proposed-public...

    LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has...